Virbac SA Asset Resilience Ratio
Virbac SA asset resilience ratio. Virbac SA (VIRP) has an Asset Resilience Ratio of 0.23% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VIRP defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Virbac SA (2011–2024)
Asset resilience ratio of Virbac SA from 2011 to 2024. This chart shows how Virbac SA's Asset Resilience Ratio has changed over time. Read Virbac SA (VIRP) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Virbac SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VIRP current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €4.31 Million | 0.23% |
| Total Liquid Assets | €4.31 Million | 0.23% |
Asset Resilience Insights
- Limited Liquidity: Virbac SA maintains only 0.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Virbac SA Industry Peers by Asset Resilience Ratio
Compare Virbac SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
|
Organon & Co
NYSE:OGN |
Drug Manufacturers - General | 4.46% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
Virbac SA Asset Resilience Ratio by Year (2011–2024)
Virbac SA asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Virbac SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.23% | €4.31 Million ≈ $5.04 Million |
€1.85 Billion ≈ $2.16 Billion |
+0.06pp |
| 2023-12-31 | 0.17% | €2.50 Million ≈ $2.92 Million |
€1.46 Billion ≈ $1.70 Billion |
-0.01pp |
| 2022-12-31 | 0.18% | €2.49 Million ≈ $2.91 Million |
€1.36 Billion ≈ $1.59 Billion |
+0.04pp |
| 2021-12-31 | 0.15% | €1.78 Million ≈ $2.08 Million |
€1.22 Billion ≈ $1.43 Billion |
-0.52pp |
| 2020-12-31 | 0.67% | €7.39 Million ≈ $8.64 Million |
€1.11 Billion ≈ $1.30 Billion |
+0.64pp |
| 2019-12-31 | 0.03% | €342.00K ≈ $399.83K |
€1.32 Billion ≈ $1.55 Billion |
-0.03pp |
| 2018-12-31 | 0.06% | €739.00K ≈ $863.97K |
€1.27 Billion ≈ $1.49 Billion |
-0.05pp |
| 2017-12-31 | 0.11% | €1.34 Million ≈ $1.57 Million |
€1.28 Billion ≈ $1.49 Billion |
+0.02pp |
| 2013-12-31 | 0.08% | €735.00K ≈ $859.29K |
€896.23 Million ≈ $1.05 Billion |
-0.11pp |
| 2011-12-31 | 0.19% | €1.14 Million ≈ $1.34 Million |
€588.63 Million ≈ $688.18 Million |
-- |
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more